<DOC>
	<DOC>NCT00004801</DOC>
	<brief_summary>OBJECTIVES: Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients with factor IX deficiency.</brief_summary>
	<brief_title>Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive monoclonal factor IX replacement therapy as inpatients. Patients with a satisfactory response receive further therapy as needed for bleeding for up to 36 months at home.</detailed_description>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Patients with factor IX deficiency.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>hematologic disorders</keyword>
	<keyword>rare disease</keyword>
</DOC>